
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is a promising oncology-focused precision medicine company with a solid pipeline of multiple clinical-stage product candidates, including darovasertib, IDE397, IDE849, IDE275, IDE161, and IDE705. The company's approach of combining small molecule drug discovery with the use of biomarkers is a notable strength, and their focus on select patient populations likely to benefit from targeted therapies presents a significant opportunity for growth. With recent updates confirming positive results and the potential for continued advancements in their clinical programs, the company has a positive outlook for continued success in the years to come.
Bears say
IDEAYA Biosciences is an oncology-focused precision medicine company with a promising clinical pipeline of targeted therapeutics. However, competition in the space is high and IDEAYA's late start in Ph 3 trials compared to its competitors may limit its market share potential. Additionally, the company's financials, including a net loss of $23.8 million in the first quarter of 2021, suggest that it may face challenges in bringing its drugs to market successfully.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares